(Q33425610)

26 July 2017

title

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule (English)

1 reference

26 July 2017

Guillaume Brachet

2

0 references

Philippe Gatault

object named as

Philippe Gatault

1

0 references

Emmanuel Gyan

object named as

Emmanuel Gyan

7

0 references

author name string

David Ternant

3

1 reference

26 July 2017

Danielle Degenne

4

1 reference

26 July 2017

Guillaume Récipon

5

1 reference

26 July 2017

Christelle Barbet

6

1 reference

26 July 2017

Valérie Gouilleux-Gruart

8

1 reference

26 July 2017

Cécile Bordes

9

1 reference

26 July 2017

Alexandra Farrell

10

1 reference

26 July 2017

Jean Michel Halimi

11

1 reference

26 July 2017

Hervé Watier

12

1 reference

26 July 2017

publication date

4 September 2015

1 reference

26 July 2017

published in

Monoclonal Antibodies

1 reference

26 July 2017

volume

7

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1205-1211

1 reference

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Population pharmacokinetics of therapeutic monoclonal antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Comparison of three different methods for measuring classical pathway complement activity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966484

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

21 June 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1086049

Eculizumab fails to inhibit generation of C5a in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1086049

Genetic variants in C5 and poor response to eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1086049

Eculizumab in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1086049

Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1086049

Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1086049

10.1080/19420862.2015.1086049

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference

26 July 2017

1 reference